Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Articles

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

The Rx Recap:  April 20-25

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: April 25, 2025

Explore the effectiveness of basic emollients in treating xerosis cutis associated with atopic dermatitis, enhancing skin hydration and barrier function.

Xerosis Management: Back to Basics with Emollients

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Sophisticated colloidal oat emollients show promise in effectively managing pediatric atopic dermatitis, enhancing skin hydration and reducing flare-ups in infants.

Can Colloidal Oat Emollients Be Used to Treat Pediatric Atopic Dermatitis?

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

clinical

Clinical

 series, host Renata Block, MMS, PA-C, a board-certified physician assistant in Chicago, Illinois, and a 

 Editorial Advisory Board member, and guest Peter Lio, MD, a board-certified dermatologist and clinical assistant professor of dermatology and pediatrics at the Northwestern Feinberg School of Medicine in Chicago, Illinois, discuss integrative approaches to managing eczema, including the use of holistic treatments, and how to incorporate these methods alongside conventional therapies.

In the first Derm Dispatch episode, Renata Block, MMS, PA-C, and Peter Lio, MD, discuss integrative approaches to managing eczema, including the use of holistic treatments.  

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine 

Lio, a dermatologist specializing in integrative approaches, emphasizes that good clinical care often naturally incorporates individualized care, blending conventional and holistic methods. One evidence-based approach he highlights is black tea compresses, which help reduce inflammation and itch, offering a simple, cost-effective alternative to bleach baths.

Lio acknowledges that while integrative options such as probiotics and vitamin D supplementation can be beneficial, patient receptivity varies. He tailors recommendations to individual preferences, avoiding overwhelming patients with too many interventions. He also discusses the nuanced role of bleach baths, noting that while they are still guideline-recommended, their mechanism may be more anti-inflammatory than antimicrobial.

Addressing steroid dependency, Lio shares his balanced perspective, recognizing their necessity in certain cases but advocating for safer, long-term alternatives. He also touches on dietary influences, emphasizing that while food triggers are rare, an anti-inflammatory diet, such as the autoimmune protocol diet, may provide some benefit. However, he cautions against unnecessary food elimination, which may increase the risk of true allergies. His patient-centered approach prioritizes evidence-based strategies while respecting individual preferences.

Block and Lio also discuss the hygiene hypothesis, noting that modern lifestyles and exposure to detergents, emulsifiers, and pollutants may negatively impact the skin barrier and microbiome. With probiotics, Lio emphasizes that although evidence is mixed, multi-strain formulations such as 

 show promise, particularly in prevention.

Lio advocates for a holistic strategy, integrating stress management techniques such as hypnotherapy and meditation, recognizing the bidirectional relationship between stress and skin inflammation.

He also shares his excitement about the growth of integrative dermatology, highlighting initiatives such as the Integrative Dermatology Symposium and the "Living Well With Eczema: A Community Workshop" event in Chicago to support education, connection, and personalized care strategies.

“We think it's so important to get these words out there. So many families feel isolated and alone. The magic is when they come together, they get to know each other, they see that they're not alone, and other people are going through the struggle. They share tips and tricks. They meet people. It's really lovely. We do something like this on the national level every year with the Eczema Expo, but this is something a little bit more intimate on a local level. We're hoping if it's a big hit here in Chicago, we're going to do more of these in different parts of the country so people can get something a little bit closer to home,” Lio said.

The “Living Well With Eczema: A Community Workshop” event, hosted by the National Eczema Association on March 22nd, brought together patients, caregivers, and health care providers for a day-long workshop to discuss eczema management strategies. Registration to the event included access to eczema sessions led by experts, educational resource packets, and networking opportunities.

register to attend Revolutionizing Atopic Dermatitis

 in Nashville, Tennessee, June 6-7. Use code DT40 for 40% off your RAD 2025 registration.

In the first Derm Dispatch episode, Renata Block, MMS, PA-C, and Peter Lio, MD, discuss integrative approaches to managing eczema, including the use of holistic treatments.

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine

The company also announced in a press release that the product received the Seal of Acceptance by the NEA.

Codex Labs Lotion is First Eczema OTC Topical to Achieve Microbiome-Friendly Certification

Researchers conducted a comprehensive review of ACD, detailing the condition’s epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic options.

Allergic Contact Dermatitis Remains Prevalent, Negatively Impacts Quality of Life

According to a survey, both patients and clinicians are unsatisfied with the current therapeutic landscape and are looking for options that better fulfill patient needs.

Patients and Providers Seek More Effective, Time-Saving Treatments for Seborrheic Dermatitis

A Finnish review highlights imprecise use of L23.8 and L23.9 codes for allergic contact dermatitis.

Increased Use of L23.8 Code in Allergic Contact Dermatitis Highlights Need for Specificity in Diagnoses

While zinc deficiency shows strong ties to SD, researchers stated vitamin D's role is less clear and may depend on genetic factors.

The Relationships Between Vitamin D, Zinc, and Seborrheic Dermatitis 

“Having a patient, and it doesn’t have to be a celebrity, talking about their experience with a disease, especially a disease that hasn't been a focus for new therapeutic in our industry, really helps to contextualize what it is that patients are experiencing,” said Patrick Burnett, MD, PhD, in an interview with 

Burnett, a board-certified dermatologist and the chief medical officer of Arcutis Biotherapeutics, recently discussed 

Arcutis’ new initiative with Odell Beckham Jr.

 to bring more awareness to seborrheic dermatitis and the positive impact of roflumilast foam (Zoryve) 0.3%.

“My seborrheic dermatitis started to bother me in my 20s when I noticed white flaky skin throughout my beard and at my hairline accompanied by a deep, burning itchy sensation that was extremely uncomfortable,” said Odell Beckham Jr. in the news release “After trying to figure out the cause for several years, I finally visited my dermatologist who diagnosed me with seb derm and prescribed Zoryve foam, which works really well for me. Now I want to help others understand the condition, find a treatment option that works for them, and get a clear win for their skin.”

Patrick Burnett, MD, PhD, Highlights Arcutis’ New Seborrheic Dermatitis Initiative With Odell Beckham Jr. 

The Impact of the Odell Beckham Jr. Partnership

Burnett first highlighted the significance of Arcutis' partnership with Odell Beckham Jr. to raise awareness about seborrheic dermatitis. Beckham’s journey mirrors that of many patients—struggling to obtain a proper diagnosis and facing a significant quality-of-life impact. By sharing his story, Beckham amplifies the conversation around a condition that has historically lacked innovation in treatment. Burnett emphasized that having a well-known figure speak about the challenges of seborrheic dermatitis can help reach both health care providers and patients, driving broader recognition and better understanding of the disease.

Diagnostic Challenges and the Importance of Awareness

Burnett discussed the diagnostic complexities of seborrheic dermatitis, particularly in differentiating it from other skin conditions such as psoriasis or atopic dermatitis. He noted that approximately 50% of the patients he sees with seborrheic dermatitis initially carry an incorrect diagnosis, often from a primary care visit years prior. Particularly in patients with skin of color, manifestations such as hypopigmentation along the hairline can lead to misdiagnoses or delays in treatment. He stressed the need for dermatologists to perform thorough examinations beyond the commonly affected areas and to consider the condition’s broader impact on patients’ lives.

approval of roflumilast foam 0.3% in December 2023

 represented the first new mechanism of action for seborrheic dermatitis treatment in over 20 years. Burnett noted that prior to roflumilast, dermatologists had limited options beyond topical steroids and antifungals, making patient management frustrating. The excitement surrounding roflumilast stems from its strong safety, tolerability, and efficacy profile, with data showing 50% of patients achieving complete clearance. Dermatologists, initially surprised that a company was investing in seborrheic dermatitis research, now appreciate having a novel treatment option to offer patients. According to Burnett, the overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.

Odell Beckham Jr. and Arcutis tackle seborrheic dermatitis in a “Clear Win for Your Skin.” News release. Arcutis Biotherapeutics. February 4, 2025. Accessed February 14, 2025. 

https://www.arcutis.com/odell-beckham-jr-and-arcutis-tackle-seborrheic-dermatitis-in-a-clear-win-for-your-skin/

Videos

The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care. 

Eczema

Latest News